Registration number: NI624941

PSC Biotech Limited

Contents

Company Information	1
Balance Sheet	2
Notes to the Unaudited Financial Statements	3 to 8

PSC Biotech Limited

Company Information

Directors

Mr Andrew John Clapham Mrs Heather Kelly

Registered office

5 Lower Catherine Street Newry Co Down Northern Ireland BT35 6BE

PSC Biotech Limited

(Registration number: NI624941)
Balance Sheet as at 31 December 2025

	Note	2025 £	2024 £
Fixed assets
Tangible assets	5	8,862	8,539
Current assets
Debtors	6	270,658	182,241
Cash at bank and in hand		17,318	16,218
		287,976	198,459
Creditors: Amounts falling due within one year	7	(106,173)	(20,301)
Net current assets		181,803	178,158
Total assets less current liabilities		190,665	186,697
Provisions for liabilities		(1,664)	(1,483)
Net assets		189,001	185,214
Capital and reserves
Called up share capital		1	1
Retained earnings		189,000	185,213
Shareholders' funds		189,001	185,214

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 9 October 2026 and signed on its behalf by:
 

......................................... Mr Andrew John Clapham Director

PSC Biotech Limited

Notes to the Unaudited Financial Statements for the year ended 31 December 2025

1	General information

The company is a private company limited by share capital, incorporated in Northern Ireland.

The address of its registered office is:
5 Lower Catherine Street
Newry
Co Down
BT35 6BE
Northern Ireland

The principal place of business is:
5 Lower Catherine Street
Newry
Co. Down
BT35 6BE

These financial statements were authorised for issue by the Board on 9 October 2026.

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis, with management having given due consideration to the company’s ability to continue as a going concern for at least the next twelve months.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of turnover can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

PSC Biotech Limited

Notes to the Unaudited Financial Statements for the year ended 31 December 2025

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Depreciation method and rate for tangible assets
Asset class	Depreciation method and rate
Office Equipment	15% Reducing Balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

PSC Biotech Limited

Notes to the Unaudited Financial Statements for the year ended 31 December 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 4 (2024 - 4).

4

Taxation

Tax charged/(credited) in the profit and loss account

	2025 £	2024 £
Deferred taxation
Arising from origination and reversal of timing differences	181	10,166

PSC Biotech Limited

Notes to the Unaudited Financial Statements for the year ended 31 December 2025

5	Tangible assets

	Furniture, fittings and equipment  £	Total £
Cost or valuation
At 1 January 2025	12,828	12,828
Additions	1,887	1,887
At 31 December 2025	14,715	14,715
Depreciation
At 1 January 2025	4,289	4,289
Charge for the year	1,564	1,564
At 31 December 2025	5,853	5,853
Carrying amount
At 31 December 2025	8,862	8,862
At 31 December 2024	8,539	8,539

6

Debtors

Current	2025 £	2024 £
Trade debtors	150,464	19,562
Other debtors	120,194	162,679
	270,658	182,241

7

Creditors

Creditors: amounts falling due within one year

	2025 £	2024 £
Due within one year
Trade creditors	17,752	13,691
Taxation and social security	9,438	2,408
Accruals and deferred income	6,170	3,218
Other creditors	72,813	984
	106,173	20,301

PSC Biotech Limited

Notes to the Unaudited Financial Statements for the year ended 31 December 2025

8	Share capital

Allotted, called up and fully paid shares

	2025		2024
	No.	£	No.	£
Ordinary of £1 each	1	1	1	1

9

Dividends

Final dividends paid

		2025 £		2024 £
Final dividend of £Nil per each Ordinary		-		-

10	Related party transactions

PSC Biotech Limited

Notes to the Unaudited Financial Statements for the year ended 31 December 2025

Directors' remuneration

The directors' remuneration for the year was as follows:

	2025 £	2024 £
Remuneration	8,144	-

Loans to related parties

2025	Other related parties £	Total £
At start of period	156,390	156,390
Advanced	102,760	102,760
Repaid	(140,372)	(140,372)
At end of period	118,778	118,778

2024	Other related parties £	Total £
At start of period	51,393	51,393
Advanced	167,871	167,871
Repaid	(62,874)	(62,874)
At end of period	156,390	156,390